Acitren

Quick links to important sections

Acitren

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acitren

Property Description
Active Ingredient Acitretin
Form Oral Capsule
Pharmacological Class Systemic Retinoid (Second-Generation)
General Purpose Controlling severe disorders of keratinization
Origin Synthetic Aromatic Retinoid (Vitamin A derivative)

What is Acitren and its Pharmacological Class?

Acitren is the trade name for the active ingredient Acitretin, a prescription-only medication classified as a systemic antipsoriatic and a specialized dermatological agent. It belongs to the high-level pharmacological class of systemic retinoids, which are chemically related to Vitamin A. Acitretin is a second-generation retinoid, distinguished from earlier compounds in its class by possessing specific pharmacological benefits. Acitren is positioned specifically for adult patients suffering from severe, chronic skin conditions that are unresponsive to less potent treatments.

Composition, Origin, and Dosage Form

The active ingredient, Acitretin, is a chemically synthetic aromatic retinoid, structurally analogous to the active metabolite of Vitamin A, retinoic acid. This controlled synthetic origin ensures standardized and predictable therapeutic properties. Acitretin is supplied for oral administration in the form of a hard capsule, and is a single active ingredient product. The formulation is particularly suited for its systemic action, which is necessary due to the compound's highly lipophilic nature; the capsule facilitates its absorption into the bloodstream and supports its bioavailability.

General Purpose of Acitretin

The general purpose of Acitretin is to control and relieve the symptoms of severe, widespread disorders of keratinization, including severe, refractory forms of psoriasis. It functions as an anti-keratinization agent by acting directly on cellular processes. By influencing gene expression within epithelial cells, it helps to normalize the disordered life cycle of skin cells, specifically regulating their excessive multiplication (proliferation) and ensuring their correct maturation (differentiation). A typical neutral use scenario involves managing conditions like erythroderma, where the drug helps address the underlying cellular cause of skin thickening and scaling.

What side effects are possible with Acitren?

Possible Side Effects and Safety Information

The safety profile for Acitren (Acitretin) is characterized by a high frequency of mucocutaneous adverse reactions and a critical, documented risk of teratogenicity. All documented side effects and safety statements are based strictly on regulatory sources.


Frequency-Classified Adverse Reactions

The most commonly observed adverse reactions are classified as Very Common in official labeling, primarily affecting the skin and mucous membranes.

Classification Examples (Organ Systems Affected)
Very Common Cheilitis, dry skin, skin exfoliation, pruritus, alopecia, dry eyes, rhinitis, elevated liver enzymes, altered blood lipids.
Common Headache, dizziness, stomatitis, joint pain (arthralgia), muscle pain (myalgia), gastrointestinal disorders.

Serious Safety Considerations

The medicine is subject to regulatory restrictions due to serious adverse reactions. The most significant is severe teratogenicity, meaning Acitren causes severe birth defects. This risk persists for an extended duration—at least three years—following the last dose, and requires absolute contraindications in pregnant patients.

Other serious events officially documented include hepatotoxicity (liver injury) and benign intracranial hypertension (pseudotumor cerebri). Psychiatric adverse effects, including altered mood and suicidal thoughts, are also noted in official regulatory documents.


Population-Specific Constraints

Acitren is strictly contraindicated in females who are pregnant or may become pregnant, as well as in patients with severe hepatic impairment. Furthermore, the label stipulates a high-level safety restriction: patients must not donate blood during therapy and for three years after cessation due to the residual teratogenic risk.

Overdose and Emergency Response

The official regulatory labeling states that acute overdose with Acitren typically results in clinical manifestations consistent with the syndrome of acute hypervitaminosis A. Documented symptoms can include severe headache, vertigo (a sensation of dizziness or spinning), and vomiting. Other associated signs reported in regulatory documents are upset stomach, dry itchy skin, loss of appetite, and bone or joint pain.


Emergency Action and Help Seeking

Upon confirmed or suspected over-exposure, the primary regulator-mandated action is the immediate withdrawal of the medication. Patients are explicitly instructed to contact a poison control center or emergency room at once when an overdose is suspected. Due to the drug’s classification of low acute toxicity and the official statement that no specific antidote is known, management is directed at providing symptomatic and supportive treatment.


Population-Specific Overdose Requirements

Overdose in female patients of childbearing potential initiates specific emergency follow-up requirements due to the established teratogenic risk (risk of severe birth defects). These mandatory post-overdose procedures, as outlined in the official prescribing information, include an immediate pregnancy test and mandated counseling concerning strict adherence to the required three-year contraceptive period.

Therapeutic Uses of Acitren

What Acitren Treats: Main Uses and Benefits

Acitren (Acitretin) is a systemic medication reserved for adult patients suffering from severe, chronic skin conditions that are unresponsive to established, conventional treatments. It is used for managing the symptoms that are related to systemic imbalance in the skin. The medication is commonly used to help with the treatment of severe psoriasis in adults.

The primary therapeutic areas include severe forms of psoriasis, specifically the pustular and erythrodermic variants, and other chronic and severe disorders of keratinization, such as Ichthyosis and Darier's disease. It is applied in clinical settings that involve acute or unstable symptom patterns. It is often used when prior, established treatments have not been sufficient.

The medication supports symptomatic relief related to physical discomfort, which may assist with easing the presence of abnormal skin thickening, scaling, and flaking. This supports improved day-to-day comfort during symptomatic periods.

“This supportive relief is commonly used when topical treatments are not providing the necessary assistance. It contributes to easing the overall symptom load.”


Quick Fact: Relief for Chronic Skin Symptoms
Acitren is considered relevant for easing widespread and persistent symptoms and may help patients cope more steadily with symptom fluctuations, providing supportive relief that assists with maintaining the stability of routine activities.

Eligibility and Restrictions for Use

Acitretin (Acitren) is a systemic retinoid with highly specific, mandatory restrictions governing its use, primarily due to the severe risk of birth defects (teratogenicity) it poses.

Populations Allowed and Restricted

Acitretin is primarily allowed for adult patients suffering from severe, chronic skin conditions such as refractory psoriasis. Use in the pediatric population (children) is generally not recommended and is contraindicated unless the potential benefits significantly outweigh the severe, documented risks of long-term therapy.

Absolute Contraindications

Regulatory agencies strictly prohibit the use of Acitretin in the following groups:

  • Pregnant women and women of childbearing potential who are not strictly adhering to a mandatory Pregnancy Prevention Programme (P.P.P.). Pregnancy must be prevented for at least three years after the final dose.
  • Breastfeeding mothers, as the medicine is known to pass into human milk.
  • Patients with severely impaired hepatic (liver) function or severely impaired renal (kidney) function.
  • Patients with chronic, abnormally elevated blood lipid values (hyperlipidemia).

Eligibility-Related Restrictions

Women of childbearing potential must not consume alcohol during treatment and for two months afterward, as alcohol promotes the formation of the highly teratogenic metabolite, etretinate. Additionally, all patients are prohibited from donating blood during therapy and for at least three years after stopping the medicine.

What should I know about interactions with other medicines?

Acitren Interactions with other medicines and products

Acitren (acitretin) has several official interaction warnings documented by regulatory authorities, primarily concerning the risk of severe toxicity and the formation of a long-acting metabolite.


Formally Contraindicated Combinations

The following combinations are strictly prohibited due to documented additive risks:

  • Methotrexate: Co-administration is contraindicated due to the risk of additive hepatotoxicity (increased liver damage).
  • Tetracycline Antibiotics: Co-administration is contraindicated due to an additive effect that increases the risk of intracranial pressure (pseudotumor cerebri).
  • Vitamin A or other Systemic Retinoids: Co-administration is contraindicated due to the risk of Hypervitaminosis A symptoms.
  • Microdosed Progestin Preparations ("Minipills"): These are not recommended or contraindicated as acitretin interferes with their contraceptive efficacy.

Pharmacokinetic and Timing Restrictions

  • Ethanol (Alcohol): Ingestion is contraindicated in women of childbearing potential, as ethanol facilitates a pharmacokinetic conversion of acitretin into the metabolite Etretinate, which has a significantly longer half-life. This prolongs the duration of teratogenic risk. Complete abstinence is required during treatment and for at least two months after cessation of therapy.
  • Food/Milk: The capsule must be taken with the main meal or with milk to ensure optimal oral absorption and systemic exposure, which is an explicit pharmacokinetic requirement on the drug label.

Mechanism of Action

How Acitretin Works

Acitretin is a synthetic retinoid that, upon biotransformation, functions as an agonist for nuclear Retinoic Acid Receptors (RARs), primarily RAR-gamma in the epidermis. Binding to these receptors enables them to act as transcription factors, initiating changes in gene expression within skin cells, particularly keratinocytes. This molecular cascade modulates the pathway for keratinocyte proliferation and differentiation. This action corrects the disorderly and excessive rate of cell production, resulting in a more regulated skin cell turnover and limiting cellular accumulation in the tissue.

Furthermore, this receptor activation influences the immune response by suppressing the transcription of various pro-inflammatory mediators and cytokines. This action restricts the signaling that drives localized tissue response and decreases the concentration of inflammatory molecules in the skin. The combined effects on cellular kinetics and inflammation result in tissue-level physiological modulation.

Dosage and Administration Information

How Acitretin (Acitren) is Used

Acitretin is a prescription-only medication supplied for oral administration in the form of hard capsules, typically available in 10 mg and 25 mg strengths. It is reserved for severe dermatological conditions and is managed under the supervision of a physician experienced in systemic retinoid therapy.


Dosing and Administration Principles

Usage Component Official Labeled Instruction
Route & Form Administered orally as a swallowed capsule.
Frequency Taken once daily (q.d.).
Timing with Food Must be taken with a main meal or milk to maximize absorption and bioavailability.
Initial Dose Generally starts at 25 mg to 50 mg daily for adults.
Maintenance Dose Adjusted based on clinical response, typically ranging from 25 mg to 50 mg daily.
Maximum Dose Should generally not exceed 75 mg per day.

Course Structure and Administration Rules

Treatment is structured around achieving resolution of the skin lesions. For conditions like severe psoriasis, the course often lasts between 6 to 9 months, after which the drug may be discontinued. For severe disorders of keratinization, such as Ichthyosis, a prolonged maintenance plan may be necessary, utilizing the lowest possible effective dose. Capsules must be swallowed whole and should not be opened or crushed. If a dose is missed, the patient should skip that dose and continue with the next scheduled dose; doubling the dose is not permitted. Dosing for older adults must be cautious due to typical age-related organ function decline.

Recent Clinical Evidence

Research evidence / Overview of studies for Acitren (Acitretin)


Evidence for Severe Psoriasis

Research into Acitretin for severe, extensive psoriasis, including the acute generalized pustular and erythrodermic forms, has largely involved short-term Randomized Controlled Trials (RCTs). These studies primarily compared Acitretin to a placebo or, in some cases, to active comparator agents. The main focus of these trials was to measure short-term symptom change, using standardized tools such as the Psoriasis Area and Severity Index (PASI) score and the Physician Global Assessment (PGA). Studies exploring short-term symptom changes in adult populations with severe psoriasis reported patterns related to changes in the severity indices (PASI and PGA) over the typical 8 to 12-week study period. Research also describes that findings were mixed regarding consistent responses across all patients.

Evidence for Severe Disorders of Keratinization

The research base for severe, chronic disorders of keratinization, such as Ichthyosis and Darier's disease, primarily consists of open-label investigations and small cohort series due to the rarity of these conditions. Studies monitored changes in key physical symptoms, including measured changes in skin scaling, thickness, and flaking, over several months. A key limitation here is the inherent modest sample sizes and the non-randomized nature of most studies. The reliance on open-label designs means that comparative evidence against placebo or other agents is lacking, making it difficult to fully characterize the range of possible outcomes.


Research on Preventing Non-Melanoma Skin Cancer (NMSC)

Acitretin was evaluated in research exploring the prevention (chemoprevention) of Non-Melanoma Skin Cancer (NMSC) in specific high-risk groups, such as adult patients who are immunosuppressed after organ transplantation. Reported outcomes described patterns related to the incidence rate of new lesions observed across study groups over the study duration, typically 1 to 2 years. However, the evidence is limited, as the follow-up durations were limited to intermediate periods. This means that long-term outcomes related to the course of the diseases are not fully established beyond the study duration.


What is Still Uncertain About Acitren Research

Several limitations and gaps exist in the current research landscape. The follow-up durations were limited in many of the key effectiveness trials, meaning long-term outcomes related to the course of the diseases are not fully established. Sample sizes were modest in studies for rarer indications, such as inherited keratinization disorders. Furthermore, evidence quality varies across studies, particularly between the high-quality, short-term RCTs for psoriasis and the smaller, open-label studies for other conditions.

Key Studies & References

  1. Acitretin - StatPearls - NCBI Bookshelf
  2. Efficacy and safety of cyclosporine a combined with acitretin in moderate-to-severe plaque psoriasis: a randomized controlled trial
  3. Pros and cons of using systemic acitretin in the paediatric population
  4. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients

Frequently Asked Questions (FAQ)

Common questions about Acitren (FAQ)


Q: How quickly does Acitren start to clear up skin conditions?

Studies and official product information indicate that the skin condition may temporarily worsen during the initial few weeks of treatment. Clinical studies suggest that patients may begin to see improvement in their lesions approximately two to six weeks after starting Acitren. The maximum therapeutic effect may take longer, often requiring three to six months of continued treatment.

Q: Do you have to take Acitren forever for skin conditions like psoriasis?

No, not necessarily. For conditions like severe psoriasis, regulatory information states that the medicine may be discontinued once the skin lesions have resolved significantly. However, for chronic disorders of keratinization, such as Ichthyosis, a prolonged maintenance plan using the lowest possible effective dose may be necessary to keep the condition controlled.

Q: What should I do if my skin seems to be getting worse after starting Acitren?

It is noted in official documentation that conditions like psoriasis can sometimes worsen temporarily when treatment is first started. If this occurs, or if new or worsening symptoms cause concern, patients are instructed to notify their prescribing physician as soon as possible.

Q: Can men taking Acitren father a child safely?

Acitretin is known to be highly teratogenic, requiring strict prevention measures for women. For men, official information states that trace amounts of the drug can be found in semen. While the risk to the fetus is considered extremely low, official labeling notes that the potential risk to an unborn child from this exposure remains unknown. Patients should ensure they discuss all reproductive plans and potential risks with their prescriber.

Q: Does using moisturizer help with the dryness caused by Acitren?

Yes. The drug commonly causes mucocutaneous side effects, including very dry skin, chapped lips (cheilitis), and dry eyes. Official patient information notes that supportive care measures, such as the use of moisturizers, lip salves, and eye lubricants, are commonly used to help relieve these side effects.

Q: Why do doctors prescribe a lower dose of Acitren to start with?

The dosing strategy is designed to be personalized, starting with an initial dose that is then adjusted by the physician. This is done because the majority of Acitren's adverse effects are considered dose-dependent. This approach is intended to optimize the balance between therapeutic effectiveness and the potential for side effects.

Q: Can a person stop taking Acitren once their skin is completely clear?

The goal of treatment is the resolution of skin lesions, after which the drug may be discontinued. However, the decision to stop treatment must be made under the supervision of a physician. For some conditions, long-term or low-dose maintenance may be necessary, and the physician will determine the full course based on the patient's condition and medical needs.

Q: Why is blood work required so often when taking Acitren?

Frequent blood tests are mandatory to check for serious, officially documented side effects. Specifically, they are needed to monitor liver function (as Acitren can elevate liver enzymes or cause liver injury) and blood lipid (fat) levels (as the drug can increase cholesterol and triglycerides).

Q: Does Acitren interact with common over-the-counter pain relievers?

Official regulatory warnings explicitly contraindicate Acitren use with specific drugs like methotrexate and tetracycline antibiotics. There is no mandatory contraindication or warning listed in core regulatory documents for common over-the-counter pain relievers (like ibuprofen or acetaminophen). Nevertheless, patients are always advised to inform their physician about all over-the-counter medicines, supplements, or products they are using.

Q: Are there any foods or drinks you should absolutely avoid while on Acitren?

Yes. Women of childbearing potential are strictly prohibited from ingesting alcohol (ethanol) during treatment and for two months after the last dose. This is because alcohol can convert Acitretin into a different metabolite (etretinate) that prolongs the risk of birth defects. Furthermore, the capsule must be taken with your main meal or with milk to ensure proper absorption.

Q: Is there a generic version of Acitren available?

Yes. Acitren is the trade name for the active ingredient acitretin. The active ingredient is generally available under its generic name (acitretin), as well as under other brand names.

Q: Does Acitren affect your ability to drive or operate machinery?

Official product information states that Acitren can cause certain side effects, such as impaired night vision (sometimes called night blindness), which may occur suddenly. Due to this risk, official warnings advise caution regarding driving or operating machinery, especially after dark.

Q: Can Acitren cause changes to fingernails or toenails?

Yes, changes to the nails are a documented side effect. Regulatory documents list possible nail changes that include inflammation of the nail wall, nail fragility, and even loosening of the fingernails (onycholysis).

Q: Is there a risk of bone or skeletal changes from long-term Acitren use?

Yes. Official warnings indicate that after long-term treatment, particularly with higher doses or in younger patients, changes to the bones may occur. These can include hyperostosis (bone overgrowth) and, less commonly, osteoporosis (thinning of the bone). Patients on prolonged therapy may have their skeletal health monitored by their prescriber.

How should Acitren be stored and disposed of?

Acitretin capsules must be stored and handled according to strict regulatory guidelines to preserve stability and prevent unintentional exposure.

Storage Conditions

Storage Requirement Specification (Official Labeling)
Temperature Range Controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection Must be protected from light, moisture, and heat; must be kept from freezing.
Container Keep in the original, closed container and keep the bottle tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal and Handling

Unused or expired Acitretin must not be disposed of in household waste or wastewater. Patients are instructed to return any unused capsules to a pharmacist or use a dedicated medicine take-back program. Due to the drug's persistence in the body, patients must not donate blood during treatment and for a mandatory period of 3 years after the last dose.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acitren found in:

A-Z Index: